Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023:2575:61-75.
doi: 10.1007/978-1-0716-2716-7_4.

Chronic Kidney Disease: Challenges in Translational Medicine

Bruno Freire Botelho  1   2 , André Luis Barreira  1   2 , Maurilo Leite Jr  1   2 , Marcelo Marcos Morales  3
Affiliations
Review

Chronic Kidney Disease: Challenges in Translational Medicine

Bruno Freire Botelho et al. Methods Mol Biol. 2023.

Abstract

Chronic kidney disease (CKD) has long been recognized as a state of progressive decline in renal function. Morbidity and mortality are well correlated to the stage of renal function decline. Approximately one million deaths are estimated to be related to CKD worldwide. They are mostly associated with cardiovascular disease as a result of concurrent hypertension, accelerated atherosclerosis, and volume overload. Even with the best current treatment, disease progression is the general rule with a small fraction who reach CKD stage 5 requiring kidney transplantation or dialysis. Transplant patients show substantial reductions in mortality and cardiovascular events, as well as improvements in quality of life. However, the capacity of health systems to deliver kidney transplantation varies worldwide with worse indicators in low-income countries. Consequently, exploring novel and better therapeutic options for CKD is mandatory. Cell-based therapy is a promising strategy for treating CKD in preclinical models, and several clinical trials involving kidney disease exhibit a favorable safety profile. This chapter aims to provide an overview of CKD and the recent results of clinical trials of cell therapy in kidney diseases.

Keywords: Cell therapy; Kidney disease; Regenerative medicine; Stem cell.

PubMed Disclaimer

References

    1. Abboud H, Henrich WL (2010) Clinical practice. Stage IV chronic kidney disease. N Engl J Med 362:56–65. https://doi.org/10.1056/NEJMcp0906797 - DOI - PubMed
    1. Abumoawad A, Saad A, Ferguson CM et al (2020) In a Phase 1a escalating clinical trial, autologous mesenchymal stem cell infusion for renovascular disease increases blood flow and the glomerular filtration rate while reducing inflammatory biomarkers and blood pressure. Kidney Int 97:793–804. https://doi.org/10.1016/j.kint.2019.11.022 - DOI - PubMed
    1. Alatab S, Shekarchian S, Najafi I et al (2019) Systemic infusion of autologous adipose tissue-derived mesenchymal stem cells in peritoneal dialysis patients: feasibility and safety. Cell J 20:483–495. https://doi.org/10.22074/cellj.2019.5591 - DOI - PubMed
    1. Barbado J, Tabera S, Sánchez A, García-Sancho J (2018) Therapeutic potential of allogeneic mesenchymal stromal cells transplantation for lupus nephritis. Lupus 27:2161–2165. https://doi.org/10.1177/0961203318804922 - DOI - PubMed
    1. Bussolati B, Camussi G (2015) Therapeutic use of human renal progenitor cells for kidney regeneration. Nat Rev Nephrol 11:695–706. https://doi.org/10.1038/nrneph.2015.126 - DOI - PubMed

LinkOut - more resources